Best annual reports 2017 - Industry rankings

Pharmaceuticals


Rated

Abbott U.S. B
Abbvie U.S. C-
Actelion Switzerland B
Active Biotech Sweden B-
Amgen U.S. C-
Amicus Therapeutics U.S. C-
Aspen Pharmacare South Africa A-
Astellas Pharma Japan B+
Astrazeneca UK A-
Baxter U.S. C+
BD (Becton Dickinson) U.S. C+
Biogen U.S. B-
Bristol-Myers Squibb U.S. B
Celgene U.S. B-
Chugai Pharmaceutical Japan B+
Cipla India C+
Coloplast Denmark C+
Daiichi Sankyo Japan B+
Dr. Reddy's Laboratories India B
Eisai Japan B+
Fresenius Medical Care Germany B+
Gilead Sciences U.S. B-
GSK (GlaxoSmithKline) UK B+
Ipsen France B+
Johnson & Johnson U.S. C+
Lilly (Eli Lilly) U.S. C+
Lundbeck Denmark B
Lupin India B
Medtronic U.S. C
Merck Germany B+
Merck & Co U.S. C
Mitsubishi Tanabe Pharma Japan B+
Neuland Laboratories India C+
Novartis Switzerland B+
Novo Nordisk Denmark A-
Octapharma Switzerland B-
Perrigo Ireland C+
Pfizer U.S. B
Roche Switzerland B+
Sanofi France B
Shire Ireland B
Sobi Sweden B+
Sun Pharma India B
Takeda Pharmaceutical Japan B
Teva Pharmaceuticals Israel C-
UCB Belgium B+
Valeant Pharmaceuticals Canada C+


Ranked

Novo Nordisk Denmark A-
Aspen Pharmacare South Africa A-
Astrazeneca UK A-
Mitsubishi Tanabe Pharma Japan B+
GSK (GlaxoSmithKline) UK B+
Novartis Switzerland B+
Roche Switzerland B+
Astellas Pharma Japan B+
Merck Germany B+
Daiichi Sankyo Japan B+
Sobi Sweden B+
Chugai Pharmaceutical Japan B+
Fresenius Medical Care Germany B+
Eisai Japan B+
UCB Belgium B+
Ipsen France B+
Abbott U.S. B
Lundbeck Denmark B
Shire Ireland B
Takeda Pharmaceutical Japan B
Dr. Reddy's Laboratories India B
Pfizer U.S. B
Sun Pharma India B
Actelion Switzerland B
Bristol-Myers Squibb U.S. B
Lupin India B
Sanofi France B
Biogen U.S. B-
Active Biotech Sweden B-
Gilead Sciences U.S. B-
Celgene U.S. B-
Octapharma Switzerland B-
Perrigo Ireland C+
Johnson & Johnson U.S. C+
Neuland Laboratories India C+
Lilly (Eli Lilly) U.S. C+
BD (Becton Dickinson) U.S. C+
Baxter U.S. C+
Cipla India C+
Valeant Pharmaceuticals Canada C+
Coloplast Denmark C+
Medtronic U.S. C
Merck & Co U.S. C
Abbvie U.S. C-
Amgen U.S. C-
Teva Pharmaceuticals Israel C-
Amicus Therapeutics U.S. C-


Compared (a)


Compared (b)


Benchmarked (a)


Benchmarked (b)


Noticed

Aspen Pharmacare

Very good introduction, based on 5 capitals; eight reasons to invest; clear strategic objectives; peer company comparatives; smart use of KPIs. All of those make up an example of integrated reporting.


Astellas Pharma

Highlights centered around the real business: R&D (topics shown later), number of new entities in the pipeline (further developed), collaborative research projects, medical representatives... Results and Plans for CSR finely summed up.


Astrazeneca

Between actual and constant rate of exchange, core and reported operating profit (net is left out) Financial highlights are more light than enlightening. More substantial content follows: e.g. Business model and life-cycle of a medicine, Marketplace, KPIs, pipeline progressions in each therapy area...


Daiichi Sankyo

Integration of business and CSR activities, challenges and strategic targets put very clearly in the Value Report. Pipeline and Major Products made intelligible, too.


Dr. Reddy's Laboratories

Gives a satisfactory account on some aspects but is too short on substance in a number of areas.


Eisai

Though not always an easy read (some pages are cluttered with texts and data), it proves a fine achiever of integrated reporting, including on Financial Capital and related Strategies.


Fresenius Medical Care

The main report is informative -e.g. about financing, risks, a detailed outlook- but a bit dull. A lively magazine goes along and provides more Living Knowledge -literally.


Lupin

The inside layout isn’t really up to the front cover magazine style but the topic-based thread does it finely, at least in the first (book) quarter. The rest is a tedious read.


Merck

The Magazine section is enticing, also in its online format. The 250-page-plus Report is more... serious, e.g. in its thorough Review of Forecast against Actual Business Developments (with a quarterly breakdown).


Mitsubishi Tanabe Pharma

Crystal-clear presentation of Business Portfolio and Processes. Pipeline highlighted right after financial and other indicators, before a substantial Message from the President and a robust chapter about Drug Discovery.


Novartis

In an effort to build Novartis into a company that can thrive no matter what the future holds (sic), we made significant changes in 2016 to create a more sustainable company. (CEO’s letter) For the present (or recent past), turn the page: most key figures went down. Why did the loss of one single US patent protection weigh so much? Nice photography.


Octapharma

A breathtaking thread made of pictures runs through the whole report of the family-owned Swiss human protein product company. Financial matters lag behind.


Pfizer

The online Annual Review gives a good... view. As to the Financial Report PDF, probably made in dullsville, many readers will quickly take their eyes off the ball.


Sun Pharma

Provides an overall picture of the global pharmaceutical industry. Length and structure as let-down.


What's your score?

What is your report total score compared to your industry peers?

The price? £ 260 or € 300 or US$ 350.
E-mail your order and invoicing references to: e.com@reportwatch.net
The availability of this information applies only to industries selected for this year’s Annual Report on Annual Reports.


Know the score

Know the detailed score breakdown for all your rated industry peers.

The price? £ 780 or € 900 or US$ 1,050.
E-mail your order and invoicing references to: e.com@reportwatch.net
The availability of this information applies only to industries selected for this year’s Annual Report on Annual Reports.


Rate

What if your company/industry has not been selected?

You may ask for what your annual report rating would be. This is free of charge.
Just send an email to e.com@reportwatch.net
Total marks and score breakdown are not disclosed except within a charged Report Scan.



Report benchmarking services by e.com

e.com provides report evaluation tools and reporting assessment services to help companies strive for higher reporting standards.

The bottom lines:

  • Mirror company value
  • Show investor value
  • Enhance report value
  • Increase stakeholder value

For a complete list of services and prices go to www.reportwatch.net/e-com/making-reports-pay-off/
For more details, service information, or placing an order, e-mail to: e.com@reportwatch.net


Q: What are the major plus and minus points in the annual report?

Quick scan A: A Quick Scan answers.
Benefit: A brief rundown of strong and weak points of the PDF or HTML report (sent via email only).

Q: What are the strengths and weaknesses of the latest annual report?

Report scan A: A Report Scan sums up.
Benefit: A scan of how report items match the 25 evaluation criteria used for the Annual Report on Annual Reports.

Q: How does the report compare with industry peers, best practice, or investment alternatives?

Peer Group Benchmarking A: : A Peer Group Benchmarking gauges.
Benefit: Benchmarks and rates a report against a peer group on all major report areas and indicators –with an aggregate scorecard and tips.